VacZineBLOG

LONDON, UK—-25th April 2012—-New Publications. Today UK-based strategic research consultancy VacZine Analytics releases a newly updated commercial market forecast for Staphylococcus aureus vaccines. MarketVIEW: Staphylococcus aureus vaccines gives a comprehensive vaccine value ($USD/volume (000s) forecast including target nosocomial and “at risk” populations until 2030 detailed to the country level. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targeting/competitive and pricing scenarios. The product contains minimum and ideal target product profiles (TPPs) to guide development along with an updated view on R&D/competitor activity.

LONDON, UK—-28th November 2011—-New Publications. Today UK-based strategic research consultancy VacZine Analytics releases a new commercial market forecast for allergic immunotherapies. MarketVIEW: allergic immunotherapies is a comprehensive commercial opportunity assessment detailing the current market for Allergen-specific immunotherapies with a patient based value/volume forecast for all relevant allergens/administration routes to 2030. The model takes into account significant future events including penetration into new countries/regions and launch of new products. A discussion is also included with regard to latest epidemiology; review of regulatory/reimbursement/pricing issues and a focus on key early stage/late stage R&D development programs.

VISIT SITE TO LEARN MORE.

LONDON, UK—-25th October 2011—-New Publications. Today UK-based strategic research consultancy VacZine Analytics releases a new commercial market forecast for Travelers’ diarrhea (TD) vaccines. MarketVIEW: Travelers’ diarrhea vaccines is comprised of a comprehensive MS Excel-based model(s) + Summary executive presentation which forecasts the potential commercial value of a new Travelers’ diarrhea vaccine across Western travelers’ markets to 2030. The model(s) contain value ($ m) and volume (mio doses) predictions for major Western countries of origin. Sensitivity analyses with regard to vaccine penetration and price are included as well as potential impact scenarios on the existing cholera/ETEC vaccine, Dukoral. VISIT SITE TO LEARN MORE.

LONDON, UK—-13th July 2011—-New Publications. Today UK-based strategic research consultancy VacZine Analytics releases a new commercial market forecast for Japanese encephalitis vaccines. MarketVIEW: Japanese encephalitis vaccines is comprised of a comprehensive MS Excel-based model(s) + Summary executive presentation which forecast the potential commercial value of Japanese encephalitis vaccine(s) across endemic markets to 2030. The model(s) contain value ($ m) and volume (mio doses) predictions for all JE endemic countries in relevant age segments in both the public and private sector down to vaccine type. LO, BASE & HI forecast scenarios model expected demand from newly adopting countries as postulated by the PATH JE project..VISIT SITE TO LEARN MORE.

LONDON, UK—-10th June 2011—-New Publications. Today UK-based strategic research consultancy VacZine Analytics releases a new commercial market forecast for Group A Streptococcus vaccines. MarketVIEW: Group A Streptococcus vaccines is a comprehensive opportunity assessment investigating the commercial potential of GAS vaccine indications for the Western developing world as well as ROW/emerging markets. The product consists of an executive presentation detailing all relevant topics pertain to GAS vaccine commercialization including priority indications, ideal target product profile, clinical development issues and competitive environment. Also included is a detailed MS Excel value/volume demand forecast to 2030 for all relevant indications/regions. This product is a ideal tool to aid early stage decision making in GAS vaccine development.VISIT SITE TO LEARN MORE.

LONDON, UK—-10th June 2011—-New Publications. Today UK-based strategic research consultancy VacZine Analytics releases a new commercial market forecast for Melanoma vaccines. MarketVIEW: Melanoma vaccines investigates the proposition of new therapeutic vaccines being used in the adjunctive treatment of melanoma. Potential indications, patient segmentation and vaccine target product profiles are discussed with a particular emphasis on GSK’s GSK2132231A. The commercial potential of putative melanoma vaccine(s) is estimated with HI and LO scenarios postulated for the major Western markets to 2030. The product is comprised of a comprehensive value/volume MS Excel-based model + Summary executive presentation and is designed to aid early stage commercial decision making in the field of oncology therapeutic vaccines.VISIT SITE TO LEARN MORE.

LONDON, UK—-4th May 2011—-New Publications. Today UK-based strategic research consultancy VacZine Analytics releases a new commercial market forecast for Dengue vaccines MarketVIEW: Dengue vaccines models the global market for a tetravalent vaccine to prevent dengue fever (DF). The product gives a comprehensive vaccine value ($USD/volume (000s) forecast for all potential age segments that would benefit from a preventative strategy in both the public and private sector of endemic countries. The model includes LO and HI forecast scenarios so the user can visualize the commercial impact of differing deployment strategies to 2030. Potential uptake of a dengue vaccine in Western travelers is also included.VISIT SITE TO LEARN MORE.